STOCKHOLM, Sweden--(BUSINESS WIRE)--Feb. 1, 2006--Symphogen A/S, Denmark and Biovitrum AB, Sweden have entered into a co-development and commercialization agreement for Sym001, Symphogen’s lead product. Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of the Newborn (HND).
